Mesenchymal stem cell

Avalon GloboCare Announces Mesenchymal Stromal Cell Therapeutic Platform for COVID-19 and Acute Graft Versus Host Disease (aGVHD)

Retrieved on: 
Thursday, September 3, 2020
Branches of biology, Medical specialties, Stem cells, Biology, Mesenchymal stem cell, Graft-versus-host disease, Stromal cell, Stroma, Hematopoietic stem cell transplantation, Bone marrow, Cytokine, Prochymal

FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the launch of its new allogeneic mesenchymal stromal cell (MSC) therapeutic platform.

Key Points: 
  • FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the launch of its new allogeneic mesenchymal stromal cell (MSC) therapeutic platform.
  • Avalon plans to develop the MSC platform as a potential therapy for COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and for bone marrow transplant related complications of acute graft versus host disease (aGVHD).
  • Mesenchymal stromal cells are typically isolated from the bone marrow, umbilical cord blood, fat tissue and other tissue types.
  • MSCs have the ability to suppress T-cell proliferation, cytokine secretion and regulate the balance of antibody-based and cell-based immune responses.

Patient Enrolment Opens in COVID-19 Clinical Trial

Retrieved on: 
Monday, August 24, 2020
Stem cells, Life sciences, Health, Branches of biology, Mesenchymal stem cell, Clinical trial, Mesoblast, Cell therapy

Following ethics committee approval (as announced on 8 May 2020), this important step represents the formal commencement of this clinical trial.

Key Points: 
  • Following ethics committee approval (as announced on 8 May 2020), this important step represents the formal commencement of this clinical trial.
  • The MEND Trial will investigate early efficacy of Cynatas proprietary Cymerus mesenchymal stem cells (MSCs) in adults admitted to intensive care with COVID-19.
  • The opening of enrolment of this clinical trial is a major achievement for Cynata.
  • We look forward to advancing this clinical trial to investigate the potential benefits our MSCs could have to treat patients in dire need during this global pandemic.

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Retrieved on: 
Wednesday, July 29, 2020
Health, Infectious diseases, Stem cells, Clinical trials, Research, Science, Pharmaceutical, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Emerging technologies, Affimer, Induced stem cells, Cell biology, Stem-cell therapy, Gene therapy, Mesenchymal stem cell

Stem cell therapies offer a very promising approach to repair the damage to lung tissues in these pulmonary diseases by controlling the immune balance.

Key Points: 
  • Stem cell therapies offer a very promising approach to repair the damage to lung tissues in these pulmonary diseases by controlling the immune balance.
  • AffyXell Therapeutics, the next-generation cell and gene therapy joint venture between Avacta and Daewoong Pharmaceutical, is developing a novel class of mesenchymal stem cell (MSC) treatments that are engineered to also produce Affimer therapies in the patient at the site of action.
  • The expansion of the agreement between Avacta, Daewoong Pharmaceutical and AffyXell announced today extends the scope of the partnership to include Affimer molecules that target viruses, such as coronaviruses, in order to develop therapies that repair the lung damage caused by COVID-19 whilst also producing neutralising Affimer molecules to prevent the progression of the disease.
  • Seng-ho Jeon, CEO of Daewoong Pharmaceutical and AffyXell Therapeutics, commented:
    It is very encouraging that AffyXell now has the opportunity to expand the application of its next-generation stem cell platform technology to target viruses.

BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update

Retrieved on: 
Monday, July 27, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Mesenchymal stem cell, Adult stem cell, Induced stem cells, Stem-cell therapy

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS).
  • BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS

Retrieved on: 
Thursday, July 23, 2020
Branches of biology, Biology, Vesicles, Exosome, Cell biology, Stem cells, Mesenchymal stem cell, Acute respiratory distress syndrome, Respiratory distress syndrome, Coronavirus disease

COVID-19 induced pneumonia carries a high fatality rate and has been associated with acute respiratory distress syndrome (ARDS).

Key Points: 
  • COVID-19 induced pneumonia carries a high fatality rate and has been associated with acute respiratory distress syndrome (ARDS).
  • Results from a study in a mouse model of lipopolysaccharide (LPS)-induced ARDS showed that intratracheal administration of NurOwn (MSC-NTF cells) derived exosomes resulted in a statistically significant improvement in multiple lung parameters.
  • Moreover, MSC-NTF cell derived exosomes exhibited a superior effect when compared to treatment with exosomes derived from nave mesenchymal stem cells (MSC) from the same donor.
  • To-date, BrainStorm Cell Therapeutics has focused its clinical development on the application of the NurOwn technology platform to neurodegenerative disorders.

Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19

Retrieved on: 
Wednesday, July 22, 2020
Medical specialties, Health, Clinical medicine, Intensive care medicine, Respiratory diseases, Stem cells, Acute respiratory distress syndrome, Respiratory physiology, Respiratory distress syndrome, Mesenchymal stem cell, Coronavirus disease, Infant respiratory distress syndrome

He is currently leading the "Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (STAT)," a United States Department of Defense supported study of MSCs for ARDS.

Key Points: 
  • He is currently leading the "Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (STAT)," a United States Department of Defense supported study of MSCs for ARDS.
  • He has been an investigator on numerous pharmacologic and biologic trials intended to treat sepsis, cardiovascular and pulmonary pathology.
  • Dr. Ware is also a lead investigator for the "Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (STAT)" study.
  • ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19.

R3 International Offering New Stem Cell Therapy for Diabetes Program in Mexico

Retrieved on: 
Wednesday, July 15, 2020
Branches of biology, Biology, Medicine, Stem cells, RTT, Biotechnology, Rheumatology, Cell biology, Stem-cell therapy, Arthritis, Mesenchymal stem cell, Type 1 diabetes

SCOTTSDALE, Ariz., July 15, 2020 /PRNewswire-PRWeb/ --R3 International is now offering a new stem cell therapy program for diabetes in Mexico, with pricing starting at only $2950.

Key Points: 
  • SCOTTSDALE, Ariz., July 15, 2020 /PRNewswire-PRWeb/ --R3 International is now offering a new stem cell therapy program for diabetes in Mexico, with pricing starting at only $2950.
  • R3 International uses mesenchymal stem cells obtained from umbilical cord tissue, from consenting donors after a scheduled c-section.
  • The stem cell treatment clinic in Mexico is only twenty minutes from the San Diego airport, and ground transportation is included.
  • In addition to effective diabetes treatment, R3 International also offers stem cell therapy for arthritis , neuropathy, stroke, dementia, MS, ALS, autism, Lyme, rheumatoid arthritis, Crohns and more.

Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19

Retrieved on: 
Friday, June 26, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Developmental biology, Induced pluripotent stem cell, IPSCS, Mesenchymal stem cell, Stem-cell therapy, IPSC

Myron Holubiak, Chief Executive Officer of Citius, commented, "We appreciate the FDA's thoughtful guidance on our unique, allogenic mesenchymal stem cells derived from induced pluripotent stem cells (iPSCs).

Key Points: 
  • Myron Holubiak, Chief Executive Officer of Citius, commented, "We appreciate the FDA's thoughtful guidance on our unique, allogenic mesenchymal stem cells derived from induced pluripotent stem cells (iPSCs).
  • We understand that iPSC-derived stem cells are not the same as adult-donor derived cells and, therefore, would require different proof of concept studies.
  • Citius's mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process.
  • The iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19.

BrainStorm to Present at the Raymond James Human Health Innovations Conference

Retrieved on: 
Thursday, June 11, 2020
Branches of biology, Biology, Stem cells, Life sciences, Biotechnology, Cell biology, Mesenchymal stem cell, Stem-cell therapy, Stem cell transplantation for articular cartilage repair

After the presentation, the management team will participate in a question and answer session with institutional investors.

Key Points: 
  • After the presentation, the management team will participate in a question and answer session with institutional investors.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS).
  • BrainStorm also recently receivedU.S.FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began inMarch 2019.

Microneedling therapeutic stem cells into damaged tissues

Retrieved on: 
Thursday, June 11, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Developmental biology, Mesenchymal stem cell, Induced stem cells

LOS ANGELES, June 10, 2020 /PRNewswire/ --Mesenchymal stem cells (MSCs) are multipotent in that they naturally replenish the cell types that build our bone, cartilage and adipose tissues.

Key Points: 
  • LOS ANGELES, June 10, 2020 /PRNewswire/ --Mesenchymal stem cells (MSCs) are multipotent in that they naturally replenish the cell types that build our bone, cartilage and adipose tissues.
  • However, clinicians often need to administer massive numbers of MSCs to reach sufficient numbers of cells that successfully engraft and remain functional over time.
  • "Microneedles have been successfully used in the past to painlessly deliver drugs to target tissues such as skin, blood vessels and eyes.
  • We demonstrate here with 'Detachable Microneedle Depots' that an analogous approach can deploy therapeutic cells at target sites," said co-corresponding author Ali Khademhosseini , the Director and CEO of the Terasaki Institute.